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Abstract 
 
 
 
 
 
 
 
Psoriasis is a chronic, immune-mediated disorder characterized by well 
demarcated, erythematous plaques covered by thick, silvery-white scales, most 
often located on the knees, elbows, sacral area and scalp. It has a significant impact 
on the patient's quality of life. 
Biological therapies revolutionized the treatment of psoriasis vulgaris but there 
has been concern regarding the use of those agents due to severe adverse reactions 
reported in patients receiving TNF-α inhibitors for various inflammatory diseases.  
The aim of this paper is to review the most important adverse reactions 
reported in patients receiving biological treatments. The most common and severe 
side effects associated with biologicals are infections, cardiac adverse reactions, 
neurologic adverse reactions, lymphomas, non-melanoma skin cancers and 
hepatobiliary disease. 
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Introduction 
Psoriasis is a chronic, immune-mediated disorder 
characterized by well demarcated, erythematous plaques 
covered by thick, silvery-white scales, most often 
located on the knees, elbows, sacral area and scalp. Any 
region however can be involved. It has a worldwide 
distribution and a prevalence of approximately 2%. It 
can occur at any age but it presents two peaks of onset: 
one at 20-30 years and the second at 50-60 years. 
Psoriasis has a significant impact on the patient's quality 
of life. Several topical and systemic therapies are 
available nowadays for the treatment of psoriasis. 
Topical treatments are difficult to apply and time-
consuming. Systemic conventional therapies are 
associated with severe adverse reactions. As a result, 
patient's compliance and adherence to treatment are low 
(1-3).  
Biological therapies revolutionized the treatment of 
psoriasis vulgaris. In Romania, they are recommended 
for patients with moderate to severe plaque type 
psoriasis unresponsive or intolerant to conventional 
therapies. Three biologicals have been largely used so 
far: infliximab, adalimumab and etanercept. All of those 
are antibodies directed against tumor necrosis factor-α 
(TNF-α). In years recent, experience with ustekinumab, 
a human monoclonal antibody directed against 
interleukin (IL) 12 and 23, has also increased. Despite 
the very good results obtained with biological 
treatments, the clinician and the patient should be aware 
of possible adverse reactions (4). 
 
Discussion 
 Adverse events in patients receiving biological 
therapies 
 Local adverse reactions 
Injection site reactions are the most frequently 
reported adverse events and occur in approximately 
17.5% of patients treated with adalimumab and 22.4% of 
patients receiving etanercept. They are mainly 
represented by erythema, edema, pruritus, hemorrhages, 
ecchymosis and low to moderate pain. The higher 
incidence of local adverse reactions in patients receiving 
etanercept is due to the more frequent administration of 
the drug. Injection site reactions are generally well 
tolerated and do not usually require interrupting the 
treatment. Topical corticosteroids and antalgics are 
sometimes useful. Varying the injection site is 
recommended (5, 6). 
Infusion reactions have been reported in 
approximately 17% of patients receiving infliximab and 
headache, dizziness, nausea, fever and pruritus are the 
most frequent symptoms. Life threatening adverse 
reactions such as convulsions and anaphylactic shock 
have been reported in approximately 0.5% of patients 
receiving infliximab. Infusion reactions can be acute or 
delayed. Acute reactions occur during the first hour and 
are represented by hives, rash, fever, bronchospasm, 
laryngopharyngeal edema, dyspnea and hypotension.  
Most cases only require decreasing the infusion rhythm 
or temporarily ceasing the infusion. Severe cases 
however necessitate stopping the treatment and 
stabilizing the patient. Delayed hypersensitivity 
reactions are represented by myalgia, arthralgia, fever, 
headaches, rash, fatigability and facial edema (5, 7). 
Infections 
Tuberculosis is one of the most important adverse 
events associated with biological therapies. Those can 
determine the reactivation of a latent tuberculosis or de 
novo infection. The risk of extrapulmonary tuberculosis 
is also higher in these patients. Given the high incidence 
of this infection in the general population, testing all 
patients prior to starting biological treatment is 
mandatory (8).  
A study performed in Sweden by Asklinget al. 
assessed the risk of developing tuberculosis of patients 
receiving TNF-α inhibitors and compared it to the risk 
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encountered in the general population. According to the 
authors, patients receiving biological therapies have a 4 
fold higher risk of developing tuberculosis than patients 
who do not receive biological treatment (9). 
Singh et al. conducted a meta-analysis of studies 
performed on patients receiving biological therapies. The 
authors included 163 randomized controlled studies with 
50,010 participants and 46 extension studies with 11 954 
participants. The authors showed that patients treated 
with TNF-α inhibitors had a higher risk of developing 
tuberculosis than patients in the control group (10). 
Cutaneous infections like cellulitis, erysipelas or 
abscess have been reported in 0.1-7% of patients treated 
with biological therapies. Superficial fungal infections of 
the skin are also more frequent in patients receiving 
biologicals. Some cases of disseminated herpes simplex 
virus infection and reactivation of the varicella-zoster 
virus have also been reported. Strangfeldet al. performed 
a study in which they included 5,040 patients with 
rheumatoid arthritis who were treated with TNF-α 
inhibitors or with disease-modifying antirheumatic drugs 
(DMARDs). The authors observed that the risk of 
developing herpes zoster was high in patients receiving 
adalimumab and infliximab but not in patients receiving 
etanercept (11). Mc Donald et al. performed a 
retrospective study in which they included 20,357 
patients treated for rheumatoid arthritis between 1998 
and 2005 and found that the risk of developing herpes 
virus is higher in patients treated with biological 
treatments, patients receiving infliximab having the 
highest risk (12). 
Opportunistic infections have been reported in 
patients receiving TNF-α inhibitors. Salmon-Ceron et al. 
performed a prospective study in which they aimed to 
describe opportunistic infections, other than 
tuberculosis, in patients with rheumatoid arthritis, 
inflammatory colitis, psoriasis vulgaris, ankylosing 
spondylitis and other inflammatory conditions treated 
with biological agents. The most common opportunistic 
infections were listeriosis, nocardiosis, infections with 
atypical mycobacteria, atypical salmonellosis, 
pneumocystosis, aspergillosis, cryptococcosis, 
leishmaniosis and disseminated cytomegalovirus 
infection. Infliximab was associated with the highest risk 
of developing opportunistic infections while etanercept 
was associated with the lowest risk (13). 
Lanternier et al. performed a prospective study 
between 2004 and 2007 in which they described the 
incidence of Legionella pneumophilapneumonia in 
patients treated with biological agents. The authors 
reported an annual incidence of 46.7 cases/100,000 
patient-years and concluded that the incidence of 
Legionella pneumophila pneumonia is high in patients 
receiving biological therapies, especially infliximab and 
adalimumab (14).  
Wissman et al. examined the pharyngeal exudate 
from 125 patients with rheumatological disorders, half of 
those being treated with infliximab. The authors 
demonstrated Pneumocystis jirovecii colonization in 
25.6% of patients and concluded that infliximab 
treatment is an important risk factor for developing this 
infection (15). 
Invasive fungal infections were reported in patients 
receiving TNF-α inhibitors. Tsiodras et al. performed a 
literature review and identified 281 cases of invasive 
fungal infections in patients treated with biological 
agents. 80% of those occurred in patients treated with 
infliximab, 16% in patients treated with etanercept and 
4% in patients receiving adalimumab (16). 
Cardiovascular adverse reactions 
Various cardiovascular adverse events have been 
associated with biological therapies. Heart failure is one 
of the most important adverse reactions reported in the 
medical literature. Setoguchi et al. showed in a study 
performed between 1994 and 2004, which included 1002 
patients treated with TNF-α inhibitors and 5593 patients 
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treated with methotrexate for rheumatoid arthritis, that 
patients receiving biological agents had a higher risk to 
develop cardiac insufficiency than patients treated with 
methotrexate (17).  Curtis et al on the other hand 
performed a study in which they included young patients 
suffering from rheumatoid arthritis or Crohn's disease 
who received biological treatment or other treatments 
and noticed no significant difference regarding the rate 
of heart failure between patients receiving anti-TNF-α 
agents and patients receiving other treatments (18). 
Other authors, like Wolfe and Michaud, showed that 
biological therapies decrease the risk of cardiac 
insufficiency. The two scientists reached this conclusion 
after analyzing data from 13,171 patients with 
rheumatoid arthritis and 2,568 patients with 
osteoarthritis (19). 
Arrhythmias were also reported in patients receiving 
infliximab. Lazzerini et al. performed a prospective 
placebo controlled study in which they included patients 
with ankylosing spondylitis and rheumatoid arthritis who 
were monitored during the infliximab infusion or 
placebo infusion, respectively. The authors showed that 
tachyarrhythmia and bradyarrhythmia were present in 
both examined groups and the difference was not 
statistically significant (20). 
Data regarding the effect of biological therapies on 
the vascular system is contradictory. Some authors 
consider that they might improve endothelial function 
and reduce the rate of cardiovascular events while others 
consider that long-time treatment with infliximab is 
proatherogenic (21). 
Cardiac output also seems to be decreased in patients 
treated with infliximab. Santos et al. performed a study 
in which they included 14 patients with rheumatoid 
arthritis with no history of cardiac insufficiency and 
measured a significant reduction of the cardiac output 
and stroke volume during the infliximab infusion (22). 
Development of anti-drug antibodies 
Biological therapies act as antigens after they are 
administered because of their protein structure. As a 
result, the immune system can create antibodies directed 
against them. The development of anti-drug antibodies 
was reported for all biological therapies. Two main types 
of anti-drug antibodies were described in the medical 
literature: neutralizing antibodies, which decrease or 
even annul the effect of the biological agent, and non-
neutralizing antibodies, which do not influence the 
pharmacological proprieties of the drug (2, 23). 
Infliximab is a chimeric mouse-human monoclonal 
antibody and its administration is frequently associated 
with the development of anti-drug antibodies which are 
generally neutralizing. Adalimumab is a fully human 
monoclonal antibody. For that reason, it was initially 
believed that it would not be recognized as non-self by 
the immune system. Recent studies however contradict 
this idea, as neutralizing antibodies directed against 
adalimumab were detected. Etanercept is a fusion 
protein produced by recombinant DNA technology. 
Anti-drug antibodies were described in patients treated 
with etanercept but these antibodies are not neutralizing 
(2). 
A study performed by Van Schie et al. showed that 
more than 90% of the antibodies directed against 
adalimumab and infliximab are neutralizing as they 
interact with the portion responsible for binding TNF-α. 
The rest of the antibodies are non-neutralizing as they 
bind to other portions of the antibodies, which are not 
involved in binding TNF-α (24). 
Kui et al. showed in a study performed on patients 
with psoriasis treated with TNF-α inhibitors that the 
presence of anti-drug antibodies is associated with 
higher severity of psoriasis and lower serum levels of 
TNF-α inhibitors (25). Murdaca et al. also showed that 
the presence of neutralizing antibodies against 
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adalimumab and infliximab decreases the chances of 
obtaining clinical remission of the disease, decreases the 
drug survival duration and increases the necessity to 
administer higher doses of biological agent (26). 
The concomitant administration of biological agents 
with methotrexate and other immunosuppressives 
decreases the risk of developing anti-drug antibodies. 
Data regarding their usefulness in patients with psoriasis 
is contradictory and additional studies are needed to 
support the efficiency of the combined treatment (27). 
Neurological adverse events 
The most important neurological side-effects 
associated with biological therapies are demyelinating 
diseases of the central nervous system, optic neuritis, 
facial paresis, peripheral neuropathy, transverse myelitis, 
Guillain-Barré syndrome and infectious diseases (28, 
29). 
Progressive multifocal leukoencephalopathy (PML), 
a potentially fatal infectious disease determined by 
activation of the John Cunningham virus, was reported 
after the treatment with monoclonal antibodies, such as 
infliximab, adalimumab, etanercept, efalizumab, 
rituximab, etc. John Cunningham virus is a double 
stranded DNA polyomavirus. It is an ubiquitous 
neurotropic virus. Studies indicate that 50-90% of adults 
have been exposed to it. PML was initially described as 
a complication of chemotherapy in hematological 
patients. Nowadays, it is considered an important 
complication of HIV infection. If patients remain 
immunosuppressed, they die within months. Efalizumab 
was voluntarily pulled off the market after three patients 
with psoriasis died from PML, as it was considered that 
the benefits do not outweigh the risk. Cases of PML 
have also been reported in patients receiving infliximab, 
adalimumab and etanercept. The incidence of the disease 
however is comparable to that found in the general 
population (29-31). 
Non-melanoma skin cancers 
TNF-α inhibitors are associated with higher rates of 
skin cancers, especially non-melanoma skin cancers. 
Askling et al. performed a meta-analysis in 2011 in 
which they included 74 randomized controlled studies 
which evaluated the short term risk of developing skin 
cancers. 15,418 patients were randomized to the group 
treated with TNF-α inhibitors and 7,486 patients were 
randomized to the control group. The authors concluded 
that patients receiving biological agents have a short 
term risk of 2.02% of developing non-melanoma skin 
cancer (32). 
The concomitant or previous administration of other 
treatments such as methotrexate, cyclosporine or PUVA 
can increase the incidence of non-melanoma skin 
cancers in patients treated with biological agents. Those 
patients must therefore avoid sun exposure and be 
closely monitored for early detection of skin cancers (5). 
Lymphomas  
The occurrence of lymphomas has been described in 
patients receiving TNF-α inhibitors for various 
disorders. Until now, however, it has been impossible to 
say if biological therapies truly increase the risk of 
developing lymphomas as data from the specialty 
literature is contradictory. Some studies concluded that 
patients treated with adalimumab and infliximab have a 
higher risk of developing lymphomas than patients 
treated with etanercept. Other studies did not find higher 
risk of developing lymphomas in patients treated with 
biological agents. It is worth mentioning that most 
studies assessing the risk of lymphoma were performed 
on patients with rheumatoid arthritis. Rheumatoid 
arthritis itself is associated with a higher risk of 
developing lymphoma. Even though the risk of 
lymphoma does not seem to be higher in patients treated 
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with biological agents, continued vigilance is warranted 
(33, 34).  
Hepatic adverse reactions 
Autoimmune hepatitis, jaundice and drug-induced 
hepatic dysfunction can all be associated with the use of 
biological therapies. The administration of TNF-α 
inhibitors in patients with hepatitis B and hepatitis C is 
not an absolute contraindication. The clinician however 
must carefully assess the risk/benefit ratio before 
recommending these treatments to patients with hepatic 
disorders. Reactivation of hepatitis B in HBsAg carriers 
was reported after the administration of biological 
agents. TNF-α plays an important role in the eradication 
of hepatitis B virus. Perez et al. performed a review of 
the literature and noticed a 39% increase in the 
reactivation rate of HBV in HBsAg carriers treated with 
anti-TNF-α agents. The risk seems to be higher in 
patients treated with infliximab (35, 36). 
TNF-α inhibitors seem to be safe in patients with 
hepatitis C. Studies show that TNF-α level is high in 
patients with hepatitis C and is associated with high 
levels of serum transaminases, histological changes and 
fibrosis. A study which included 216 patients with 
hepatitis C treated with TNF-α inhibitors showed that 
only 3 patients required terminating treatment due to 
hepatitis C reactivation. The viral load remains constant 
or even decreases after short term treatment with 
biological agents (37, 38). However, some cases of 
hepatocellular carcinoma were reported in patients with 
HCV who received long term treatment for psoriasis 
vulgaris. Regular follow-ups are therefore mandatory in 
those patients (38, 39). 
 Should safety data from other inflammatory 
disorders be extrapolated to psoriasis? 
Most data regarding the safety of biological therapies 
comes from patients treated for rheumatic diseases and 
from inflammatory bowel disease. These disorders are 
associated with comorbidities and require specific 
treatments. Some authors therefore suggested that safety 
data from other inflammatory disorders should not be 
applied to patients with psoriasis. To support this idea, 
Garcia-Doval et al. compared data from two national 
drug safety registers: Biobadaser, the registry for 
rheumatic diseases and Biobadaderm, the registry for 
psoriasis. The authors showed that the risk of serious 
adverse events is almost two fold higher in patients with 
rheumatoid arthritis than in patients with psoriasis 
treated with anti-TNFα inhibitors. The authors also 
showed that patients receiving biological therapies for 
rheumatoid arthritis have a higher risk of developing 
infections, cardiac disorders, respiratory disorders, and 
infusion related reactions while patients receiving 
biologicals for psoriasis have a higher risk of developing 
skin and subcutaneous tissue disorders and hepatobiliary 
diseases (40).  
A study which included 173 psoriasis patients who 
were prospectively followed for 5 years also showed that 
long-term treatment with biologicals is safe in this group 
of patients, the rate of malignancies, serious infections 
and serious cardiovascular events being comparable with 
the general population incidence rate. The authors also 
found that psoriatic patients treated with anti-TNF-α 
agents have a higher risk of developing skin 
malignancies, probably due to previous exposure to UV-
therapies and immunosuppressive drugs, but also 
because these patients are more closely followed by 
dermatologists (41). 
 
Conclusions 
Psoriasis vulgaris is a chronic, inflammatory disease 
with a great impact on the patient's quality of life. TNF-α 
inhibitors have revolutionized the treatment of psoriasis 
but there has been some concern regarding the use of 
those agents due to severe adverse reactions reported in 
patients receiving biological therapies for various 
inflammatory diseases. The most important severe 
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adverse reactions associated with biologicals are 
infections, cardiac adverse reactions, neurologic adverse 
reactions, lymphomas, non-melanoma skin cancers and 
hepatobiliary disease. Most adverse events were reported 
in patients receiving anti-TNFα agents for rheumatic 
diseases and the safety data were extrapolated to 
psoriatic patients. New studies performed on psoriatic 
patients treated with biological agents are therefore 
required in order to establish the safety profile of the 
drugs in this particular group. 
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